Cargando…

Risk factors in the development of stem cell therapy

Stem cell therapy holds the promise to treat degenerative diseases, cancer and repair of damaged tissues for which there are currently no or limited therapeutic options. The potential of stem cell therapies has long been recognised and the creation of induced pluripotent stem cells (iPSC) has booste...

Descripción completa

Detalles Bibliográficos
Autores principales: Herberts, Carla A, Kwa, Marcel SG, Hermsen, Harm PH
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070641/
https://www.ncbi.nlm.nih.gov/pubmed/21418664
http://dx.doi.org/10.1186/1479-5876-9-29
_version_ 1782201397930885120
author Herberts, Carla A
Kwa, Marcel SG
Hermsen, Harm PH
author_facet Herberts, Carla A
Kwa, Marcel SG
Hermsen, Harm PH
author_sort Herberts, Carla A
collection PubMed
description Stem cell therapy holds the promise to treat degenerative diseases, cancer and repair of damaged tissues for which there are currently no or limited therapeutic options. The potential of stem cell therapies has long been recognised and the creation of induced pluripotent stem cells (iPSC) has boosted the stem cell field leading to increasing development and scientific knowledge. Despite the clinical potential of stem cell based medicinal products there are also potential and unanticipated risks. These risks deserve a thorough discussion within the perspective of current scientific knowledge and experience. Evaluation of potential risks should be a prerequisite step before clinical use of stem cell based medicinal products. The risk profile of stem cell based medicinal products depends on many risk factors, which include the type of stem cells, their differentiation status and proliferation capacity, the route of administration, the intended location, in vitro culture and/or other manipulation steps, irreversibility of treatment, need/possibility for concurrent tissue regeneration in case of irreversible tissue loss, and long-term survival of engrafted cells. Together these factors determine the risk profile associated with a stem cell based medicinal product. The identified risks (i.e. risks identified in clinical experience) or potential/theoretical risks (i.e. risks observed in animal studies) include tumour formation, unwanted immune responses and the transmission of adventitious agents. Currently, there is no clinical experience with pluripotent stem cells (i.e. embryonal stem cells and iPSC). Based on their characteristics of unlimited self-renewal and high proliferation rate the risks associated with a product containing these cells (e.g. risk on tumour formation) are considered high, if not perceived to be unacceptable. In contrast, the vast majority of small-sized clinical trials conducted with mesenchymal stem/stromal cells (MSC) in regenerative medicine applications has not reported major health concerns, suggesting that MSC therapies could be relatively safe. However, in some clinical trials serious adverse events have been reported, which emphasizes the need for additional knowledge, particularly with regard to biological mechanisms and long term safety.
format Text
id pubmed-3070641
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30706412011-04-05 Risk factors in the development of stem cell therapy Herberts, Carla A Kwa, Marcel SG Hermsen, Harm PH J Transl Med Review Stem cell therapy holds the promise to treat degenerative diseases, cancer and repair of damaged tissues for which there are currently no or limited therapeutic options. The potential of stem cell therapies has long been recognised and the creation of induced pluripotent stem cells (iPSC) has boosted the stem cell field leading to increasing development and scientific knowledge. Despite the clinical potential of stem cell based medicinal products there are also potential and unanticipated risks. These risks deserve a thorough discussion within the perspective of current scientific knowledge and experience. Evaluation of potential risks should be a prerequisite step before clinical use of stem cell based medicinal products. The risk profile of stem cell based medicinal products depends on many risk factors, which include the type of stem cells, their differentiation status and proliferation capacity, the route of administration, the intended location, in vitro culture and/or other manipulation steps, irreversibility of treatment, need/possibility for concurrent tissue regeneration in case of irreversible tissue loss, and long-term survival of engrafted cells. Together these factors determine the risk profile associated with a stem cell based medicinal product. The identified risks (i.e. risks identified in clinical experience) or potential/theoretical risks (i.e. risks observed in animal studies) include tumour formation, unwanted immune responses and the transmission of adventitious agents. Currently, there is no clinical experience with pluripotent stem cells (i.e. embryonal stem cells and iPSC). Based on their characteristics of unlimited self-renewal and high proliferation rate the risks associated with a product containing these cells (e.g. risk on tumour formation) are considered high, if not perceived to be unacceptable. In contrast, the vast majority of small-sized clinical trials conducted with mesenchymal stem/stromal cells (MSC) in regenerative medicine applications has not reported major health concerns, suggesting that MSC therapies could be relatively safe. However, in some clinical trials serious adverse events have been reported, which emphasizes the need for additional knowledge, particularly with regard to biological mechanisms and long term safety. BioMed Central 2011-03-22 /pmc/articles/PMC3070641/ /pubmed/21418664 http://dx.doi.org/10.1186/1479-5876-9-29 Text en Copyright ©2011 Herberts et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Herberts, Carla A
Kwa, Marcel SG
Hermsen, Harm PH
Risk factors in the development of stem cell therapy
title Risk factors in the development of stem cell therapy
title_full Risk factors in the development of stem cell therapy
title_fullStr Risk factors in the development of stem cell therapy
title_full_unstemmed Risk factors in the development of stem cell therapy
title_short Risk factors in the development of stem cell therapy
title_sort risk factors in the development of stem cell therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070641/
https://www.ncbi.nlm.nih.gov/pubmed/21418664
http://dx.doi.org/10.1186/1479-5876-9-29
work_keys_str_mv AT herbertscarlaa riskfactorsinthedevelopmentofstemcelltherapy
AT kwamarcelsg riskfactorsinthedevelopmentofstemcelltherapy
AT hermsenharmph riskfactorsinthedevelopmentofstemcelltherapy